CN106456747A - 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法 - Google Patents

用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法 Download PDF

Info

Publication number
CN106456747A
CN106456747A CN201580034007.8A CN201580034007A CN106456747A CN 106456747 A CN106456747 A CN 106456747A CN 201580034007 A CN201580034007 A CN 201580034007A CN 106456747 A CN106456747 A CN 106456747A
Authority
CN
China
Prior art keywords
antagonist
agonist
test point
methods according
immunologic test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580034007.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·福伊
斯蒂法尼·曼德尔
瑞安·朗特里
A·弗兰祖斯奥夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Publication of CN106456747A publication Critical patent/CN106456747A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201580034007.8A 2014-05-13 2015-05-08 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法 Pending CN106456747A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992788P 2014-05-13 2014-05-13
US61/992,788 2014-05-13
PCT/US2015/029855 WO2015175334A2 (en) 2014-05-13 2015-05-08 Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist

Publications (1)

Publication Number Publication Date
CN106456747A true CN106456747A (zh) 2017-02-22

Family

ID=53499070

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580034007.8A Pending CN106456747A (zh) 2014-05-13 2015-05-08 用表达肿瘤抗原的重组痘病毒和免疫检查点分子拮抗剂或激动剂治疗癌症的组合疗法

Country Status (13)

Country Link
US (1) US20170266270A1 (https=)
EP (1) EP3142690B1 (https=)
JP (1) JP6747981B2 (https=)
KR (1) KR102499737B1 (https=)
CN (1) CN106456747A (https=)
AU (1) AU2015259510B2 (https=)
CA (1) CA2946418C (https=)
DK (1) DK3142690T3 (https=)
ES (1) ES2913236T3 (https=)
IL (1) IL248507B (https=)
NZ (1) NZ725459A (https=)
RU (1) RU2724433C2 (https=)
WO (1) WO2015175334A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847534A (zh) * 2015-04-17 2018-03-27 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
CN111050790A (zh) * 2017-08-24 2020-04-21 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
CN111556760A (zh) * 2017-11-06 2020-08-18 纪念斯隆-凯特林癌症中心 作为疫苗免疫佐剂的热灭活的牛痘病毒
CN113056284A (zh) * 2018-11-20 2021-06-29 巴法里安诺迪克有限公司 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
CN114867491A (zh) * 2019-11-20 2022-08-05 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
US11426460B2 (en) 2015-02-25 2022-08-30 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US11541087B2 (en) 2016-02-25 2023-01-03 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11884939B2 (en) 2017-05-12 2024-01-30 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US12036279B2 (en) 2016-02-25 2024-07-16 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US12252702B2 (en) 2018-09-15 2025-03-18 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
ES2833425T3 (es) * 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
EP4523756A3 (en) * 2015-02-13 2025-05-28 Transgene Immunotherapeutic vaccine and antibody combination therapy
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
CN109312364A (zh) * 2016-03-18 2019-02-05 河谷细胞有限公司 用于感染树突状细胞的多模式载体
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
CN107281474A (zh) * 2016-04-11 2017-10-24 中国科学院上海巴斯德研究所 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
EP4253419A3 (en) 2016-06-02 2024-05-22 Ultimovacs ASA A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
HRP20211703T1 (hr) * 2016-11-02 2022-02-04 Jounce Therapeutics, Inc. Protutijela protiv pd-1 i njihova upotreba
KR200486872Y1 (ko) 2016-11-16 2018-07-10 김영선 가변형 조립식 책상
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
US20190367568A1 (en) * 2018-02-05 2019-12-05 Nantbio, Inc. Calreticulin and fusion proteins
TWI905535B (zh) 2018-04-23 2025-11-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CA3133971A1 (en) * 2019-03-20 2020-09-24 Turnstone Biologics Inc. Sequential heterologous boost oncolytic viral mmunotherapy
US20230405105A1 (en) 2019-09-20 2023-12-21 Transgene Sa Combination of a poxvirus encoding hpv polypeptides with an anti-pd-l1 antibody
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121168A1 (en) * 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1119354A (en) * 1914-01-05 1914-12-01 Adelbert Armstrong Broom-holder.
US1391972A (en) * 1920-08-05 1921-09-27 American Cotton Oil Company Method and apparatus for molding soap

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121168A1 (en) * 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESPENSCHIED ET AL: "CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model", 《JOURNAL OF IMMUNOLOGY》 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11426460B2 (en) 2015-02-25 2022-08-30 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US12397029B2 (en) 2015-04-17 2025-08-26 Memorial Sloan Kettering Cancer Center Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
CN107847534A (zh) * 2015-04-17 2018-03-27 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
US11986503B2 (en) 2016-02-25 2024-05-21 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11541087B2 (en) 2016-02-25 2023-01-03 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US12036279B2 (en) 2016-02-25 2024-07-16 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US11884939B2 (en) 2017-05-12 2024-01-30 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN111050790B (zh) * 2017-08-24 2024-07-12 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
CN111050790A (zh) * 2017-08-24 2020-04-21 巴法里安诺迪克有限公司 通过静脉内施用重组mva和抗体治疗癌症的组合疗法
CN111556760A (zh) * 2017-11-06 2020-08-18 纪念斯隆-凯特林癌症中心 作为疫苗免疫佐剂的热灭活的牛痘病毒
US12252702B2 (en) 2018-09-15 2025-03-18 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113056284A (zh) * 2018-11-20 2021-06-29 巴法里安诺迪克有限公司 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
CN114867491A (zh) * 2019-11-20 2022-08-05 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
CN114867491B (zh) * 2019-11-20 2025-08-15 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒

Also Published As

Publication number Publication date
RU2724433C2 (ru) 2020-06-23
WO2015175334A3 (en) 2016-02-04
CA2946418A1 (en) 2015-11-19
US20170266270A1 (en) 2017-09-21
KR20170003556A (ko) 2017-01-09
RU2016148311A (ru) 2018-06-18
EP3142690A2 (en) 2017-03-22
IL248507B (en) 2022-07-01
NZ725459A (en) 2023-04-28
JP6747981B2 (ja) 2020-08-26
AU2015259510B2 (en) 2020-10-01
RU2016148311A3 (https=) 2018-12-26
AU2015259510A1 (en) 2016-11-10
JP2017515837A (ja) 2017-06-15
IL248507A0 (en) 2016-12-29
EP3142690B1 (en) 2022-02-23
WO2015175334A2 (en) 2015-11-19
DK3142690T3 (da) 2022-05-09
ES2913236T3 (es) 2022-06-01
CA2946418C (en) 2023-07-04
KR102499737B1 (ko) 2023-02-13

Similar Documents

Publication Publication Date Title
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法
US20210205429A1 (en) Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
KR102499737B1 (ko) 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법
AU2014347004A1 (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
US8313740B2 (en) Methods for treating cancer with a recombinant MVA expressing HER-2
US20170106065A1 (en) Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
US20150283220A1 (en) Methods and compositions for the treatment of cancer
NZ725519B2 (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170222